Page last updated: 2024-09-04

tezosentan and Dyspnea

tezosentan has been researched along with Dyspnea in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Teerlink, JR1
Bourge, RC; Cleland, JG; Cotter, G; Frey, A; Jondeau, G; Kobrin, I; Krum, H; Lewsey, J; McMurray, JJ; Metra, M; O'Connor, CM; Parker, JD; Rainisio, M; Teerlink, JR; Torre-Amione, G; van Veldhuisen, DJ1

Reviews

1 review(s) available for tezosentan and Dyspnea

ArticleYear
Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure.
    American heart journal, 2003, Volume: 145, Issue:2 Suppl

    Topics: Acute Disease; Drug Approval; Dyspnea; Forecasting; Heart Failure; Hospitalization; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Pyridines; Randomized Controlled Trials as Topic; Severity of Illness Index; Simendan; Tetrazoles; Treatment Outcome; Vasodilator Agents

2003

Trials

1 trial(s) available for tezosentan and Dyspnea

ArticleYear
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
    JAMA, 2007, Nov-07, Volume: 298, Issue:17

    Topics: Acute Disease; Aged; Cardiac Output; Double-Blind Method; Dyspnea; Endothelin Receptor Antagonists; Female; Heart Failure; Humans; Infusions, Intravenous; Male; Pulmonary Wedge Pressure; Pyridines; Tetrazoles; Treatment Outcome; Vascular Resistance; Vasodilator Agents

2007